Business
Roche Cancer Collaboration
Roche Cancer Collaboration.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n Sareum Holdings PLC\n26 September 2006\n\n\nFor immediate release 26 September 2006\n\n\n SAREUM HOLDINGS PLC\n (\"Sareum\" or the \"Company\")\n\n Cancer Collaboration with Roche\n\nSareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery\nbusiness, is pleased to announce that it has entered into a collaborative\nagreement with Roche, one of the world's leading research-oriented healthcare\ngroups, to provide protein structure determination capabilities to accelerate\nRoche's cancer drug discovery research.\n\nSareum will use its skills in protein engineering and high throughput protein\nstructure determination to illustrate the precise nature of how Roche's\npotential drug candidates interact with target receptor proteins. This detailed\nstructural information will support Roche's scientists in their search for new\nand improved cancer therapeutics by assisting lead optimisation results and\nproviding co-complex structures for Roche's compounds.\n\nFinancial terms of the agreement were not disclosed.\n\nCommenting on the agreement, Sareum's Chief Executive Officer, Dr Tim Mitchell,\nsaid: \"We are delighted that Roche has chosen Sareum as their partner in protein\nstructure determination. This is a further important collaboration that Sareum\nhas signed with a major global pharmaceutical company and further validation\nthat Sareum is a partner of choice for structure-based drug discovery.\"\n\n\nFor further information please contact:\n\nSareum Holdings 01223 497700\nTim Mitchell, Chief Executive Officer\n\nBuchanan Communications 020 7466 5000\nTim Anderson, Mary-Jane Johnson\n\n\nAbout Sareum Holdings plc\n\nSareum Holdings plc is a structure-based drug discovery business headquartered\nin Cambridge, UK. Sareum Limited was formed in August 2003 to discover new drugs\nfor the treatment of cancer and to provide a range of drug discovery services to\nthe pharmaceutical industry. Sareum's unique approach aims to halve the time it\ntakes to discover new drug candidates.\n\nA structure-based approach to drug discovery relies on knowledge of the\nthree-dimensional structure of the proteins that cause disease. Once the\nstructure is known, potential drugs are designed to 'lock-in' to the protein\nwith the aim of reversing or arresting a disease's progression. Knowledge of the\nstructure of the potential drugs...